It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Oncogene amplification, a major driver of cancer pathogenicity, is often mediated through focal amplification of genomic segments. Recent results implicate extrachromosomal DNA (ecDNA) as the primary driver of focal copy number amplification (fCNA) - enabling gene amplification, rapid tumor evolution, and the rewiring of regulatory circuitry. Resolving an fCNA’s structure is a first step in deciphering the mechanisms of its genesis and the fCNA’s subsequent biological consequences. We introduce a computational method, AmpliconReconstructor (AR), for integrating optical mapping (OM) of long DNA fragments (>150 kb) with next-generation sequencing (NGS) to resolve fCNAs at single-nucleotide resolution. AR uses an NGS-derived breakpoint graph alongside OM scaffolds to produce high-fidelity reconstructions. After validating its performance through multiple simulation strategies, AR reconstructed fCNAs in seven cancer cell lines to reveal the complex architecture of ecDNA, a breakage-fusion-bridge and other complex rearrangements. By reconstructing the rearrangement signatures associated with an fCNA’s generative mechanism, AR enables a more thorough understanding of the origins of fCNAs.
Focal copy number amplifications (fCNAs), which drive cancer pathogenicity, arise by a number of mechanisms and can be challenging to call. Here the authors present AmpliconReconstructor for precise and scalable fCNA reconstruction using optical mapping and next-generation sequencing data.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of California at San Diego, Bioinformatics and Systems Biology Graduate Program, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California at San Diego, Department of Computer Science and Engineering, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
2 Salk Institute for Biological Studies, Plant Molecular and Cellular Biology Laboratory, La Jolla, USA (GRID:grid.250671.7) (ISNI:0000 0001 0662 7144)
3 University of California at San Diego, Department of Computer Science and Engineering, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
4 University of California at San Diego, Biomedical Sciences Graduate Program, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California at San Diego, Ludwig Institute for Cancer Research, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
5 University of California at San Diego, Ludwig Institute for Cancer Research, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
6 Bionano Genomics, Inc., San Diego, USA (GRID:grid.470262.5) (ISNI:0000 0004 0473 1353)
7 University of California at San Diego, Bioinformatics and Systems Biology Graduate Program, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
8 University of California at San Diego, Ludwig Institute for Cancer Research, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California at San Diego, Moores Cancer Center, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); University of California at San Diego, Department of Pathology, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)